RETINOBLASTOMA ASSOCIATED WITH TOTAL EXUDATIVE RETINAL DETACHMENT: Treatment and Outcomes.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
27
4
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
To study the clinical presentation, treatment, and outcomes of eyes presenting with retinoblastoma and total retinal detachment. A retrospective study of 50 eyes in 43 patients. The mean age at presentation was 15 months (median, 9 months). Retinoblastoma-associated total retinal detachment was unilateral (n = 36; 84%) or bilateral (n = 7; 16%). The mean tumor basal diameter was 17 mm (median, 18 mm), and the mean tumor thickness was 13 mm (median, 12 mm). Associated features included subretinal seeds (n = 26; 52%), vitreous seeds (n = 13; 26%), and subretinal exudation (n = 4; 8%). Based on eighth edition of American Joint Committee on Cancer classification, the tumors were classified as cT2a (n = 19; 38%), cT2b (n = 28; 56%), or cT3c (n = 3; 6%). Primary treatment included intravenous (n = 48; 96%) or intraarterial chemotherapy (n = 2; 4%). Over a mean follow-up period of 30 months (median, 29 months; range, 7-62 months), retinal detachment resolved in 41 eyes (82%), tumor recurrence was noted in 39 eyes (78%), globe salvage was achieved in 35 eyes (70%), and one patient (2%) died due to metastasis. Relatively high tumor recurrence rate is noted in retinoblastoma presenting with total retinal detachment. With appropriate treatment, 70% of the globes can be salvaged.
Identifiants
pubmed: 36728575
doi: 10.1097/IAE.0000000000003734
pii: 00006982-202305000-00013
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
808-814Références
Pandey AN. Retinoblastoma: an overview. Saudi J Ophthalmol 2014;28:310–315.
Rowlands MA, Mondesire-Crump I, Levin A, et al. Total retinal detachments due to retinoblastoma: outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery. PLoS One 2018;13:e0195395.
Shields CL, Kaliki S, Shah SU, et al. Effect of intraarterial chemotherapy on retinoblastoma-induced retinal detachment. Retina 2012;32:799–804.
El Hamichi S, Acon D, Kon Graversen V, et al. Persistent retinal detachment in retinoblastoma: the challenges. J Ophthalmol 2020;2020:1–5.
Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006;113:2276–2280.
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North America 2005;18:41–53.
Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006;47:801–805.
Mallipatna AC, Gallie BL, Chévez-Barrios P, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer; 2017:819–831.
Ancona-Lezama D, Garza-Garza LA, Ruiz-Lozano RE, et al. Diffuse infiltrative retinoblastoma with retinal detachment in “cinnamon-roll” configuration: a case report. J Am Assoc Pediatr Ophthalmol Strabismus 2021;25:59–62.
Elaraoud I, Ch’ng S, Karl D, et al. Management of retinal detachment in retinoblastoma with globe conserving treatment. J Curr Ophthalmol 2019;31:43–48.
Lim Frcsed TH, Robertson DM. Presumed rhegmatogenous retinal detachment in patients with retinoblastoma. Retina 2000;20:22–27.
Madreperla SA, Hungerford JL, Cooling RJ, et al. Repair of late retinal detachment after successful treatment of retinoblastoma. Retina 2000;20:28–32.
Mullaney PB, Abboud EB, Al-Mesfer SA. Retinal detachment associated with type III retinoblastoma regression after cryotherapy and external-beam radiotherapy. Am J Ophthalmol 1997;123:140–142.
Bovey EH, Fernandez-Ragaz A, Héon E, et al. Rhegmatogenous retinal detachment after treatment of retinoblastoma. Ophthalmic Genet 1999;20:141–151.
Yousef YA, Manna M, Khalil MB, Nawaiseh I. Surgical repair of rhegmatogenous retinal detachment in eyes harboring active retinoblastoma. Ophthalmic Genet 2016;37:314–317.
Shanmugam PM. Commentary: the shift to intra-arterial chemotherapy - relevance in Indian context. Indian J Ophthalmol 2019;67:2011–2012.
Shields CL, Say EAT, Pefkianaki M, et al. Rhegmatogenous retinal detachment after intraarterial chemotherapy for retinoblastoma: the 2016 Founders Award Lecture. Retina 2017;37:1441–1450.
Palioura S, Gobin YP, Brodie SE, et al. Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment. Pediatr Blood Cancer 2012;59:859–864.
Berry JL, Shih G, Moysidis SN, et al. Patterns of subretinal fluid resolution in group D eyes treated with chemoreduction: experience from the Children's hospital Los angeles/university of southern California. Ophthalmic Genet 2016;37:400–403.
Berry JL, Kogachi K, Murphree AL, et al. A review of recurrent retinoblastoma: children's hospital Los Angeles classification and treatment guidelines. Int Ophthalmol Clin 2019;59:65–75.
Kaliki S, Vempuluru VS, Priya Y, Mohamed A. Risk factors for recurrent retinoblastoma after intravenous chemotherapy. Int Ophthalmol 2021;41:2033–2039.
Abdelhakim AH, Francis JH, Marr BP, et al. Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function. Br J Ophthalmol 2017;101:623–628.